公开(公告)号：US20160367560A1

公开(公告)日：2016-12-22

申请号：US15185948

申请日：2016-06-17

申请人： UCB Biopharma SPRL

发明人： Anne Michel ,  Patrick Downey ,  Florian Montel ,  Dieter Scheller ,  Bernard Christophe

IPC分类号： A61K31/522 ,  A61K9/20 ,  A61K31/454

CPC分类号： A61K31/522 ,  A61K9/20 ,  A61K31/195 ,  A61K31/198 ,  A61K31/423 ,  A61K31/445 ,  A61K31/451 ,  A61K31/454 ,  A61K31/495 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5415 ,  A61K45/06 ,  A61K2300/00

摘要： The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.